ESC 365 - Safety, tolerability and discontinuation causes of sacubitril/valsartan treatment in patients with heart failure and reduced ejection fraction attending to an outpatient heart failure clinic.

HFA Premium Access

Safety, tolerability and discontinuation causes of sacubitril/valsartan treatment in patients with heart failure and reduced ejection fraction attending to an outpatient heart failure clinic.

Session: Poster Session 3 - Chronic Heart Failure – Treatment

Topic: Pharmacotherapy

Speaker: Doctor M. Rizzo (Sabadell, ES)

Event: Heart Failure 2019

Congress Presentation

Add to my library

About the speaker

Doctor Marcelo Rizzo

Hospital Universitari Parc Tauli de Sabadell, Sabadell (Spain)

0 follower

56 more presentations in this session

Effects of mineralocorticoid ceceptor antagonists (MRA) in heart failure patients after up to 12 months of follow-up.

Speaker: Doctor L. Buttigieg (Msida, MT)

Sacubitril valsartan, a multicentric experience

Speaker: Mr F. Cortes (Sevilla, ES)

Reduction of NT-proBNP in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction in short-term treatment with empagliflozin on top of existing therapy

Speaker: Professor B. Kanazirev (Varna, BG)

Effects of sacubitril/valsartan on real-world patients with heart failure due to non-ischemic cardiomyopathy

Speaker: Associate Professor C. Hsu (Taipei, TW)

Effects of ivabradine on patients with depressed left ventricular ejection fraction after cardiac resynchronization therapy

Speaker: Doctor C. Hsieh (Taipei, TW)

Access the full session

Poster Session 3 - Chronic Heart Failure – Treatment

Speakers: Doctor M. Rizzo, Doctor L. Buttigieg, Mr F. Cortes, Professor B. Kanazirev, Associate Professor C. Hsu...

About the event

Heart Failure 2019

25 May - 28 May 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources